-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-516236-10-00
4
Triple-negative breast cancer
-
2025-522204-24-00
4
Drug-Related Side Effects and Adverse Reactions
-
2025-523269-31-00
3
2026-06-02
Hormone receptor-positive early breast cancer in post-menopausal women
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2024-520027-88-00
4
2026-02-12
Patients with hormone receptor-positive (HR+) breast cancer
-
2023-505661-89-00
4
2025-12-19
Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2025-521040-37-00
5
2025-11-26
HER2-positive early breast cancer
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2024-512360-55-00
4
2025-06-30
Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2022-500544-38-00
5
2023-06-05
Advanced Breast Cancer
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2023-506784-33-00
5
2021-01-19
RET fusion-Positive NSCLC
-
2025-521284-12-00
5
2026-03-05
Non-small cell lung cancer
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2025-521441-24-00
7
2026-01-19
Advanced or Metastatic Solid Tumors
-
2024-514113-35-01
6
2025-11-03
Persistent atrial fibrillation
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-515984-68-00
4
2025-05-20
Non-small cell lung cancer (NSCLC)
-
2023-508112-35-00
4
2025-04-15
ROS1-positive non-small cell lung cancer (NSCLC) with active brain met
-
2024-512960-75-00
5
2025-02-04
Resectable Non-small cell lung cancer
-
2023-505077-32-00
5
2025-01-28
Locally-advanced or metastatic non-squamous non-small cell lung cancer